Figure 2
From: Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement

Survival of patients depending on the presence of predictive factors (mutations in the EGFR gene, rearrangements of ALK and ROS1 genes, PD-L1 expression) and the type of treatment (MedCalc Statistical Software version 18.11.6, https://www.medcalc.org).